Geheimtipp? Da läuft schon seit einigen Jahren etwas. Es scheint eine Sache zu sein, die ein bestimmtes Potential in sich tragen könnte. Ich habe gelesen, dass in Deutschland ein Dr. Giese im Tierversuch und in vitro (im Reagenzglas) mit Chloroquin arbeitet. Man kann bei google unter
Giese Chloroquin suchen.
(Den ersten Hinweis auf Chloroquin verdanke ich dem unermüdlichen W.H. aus der Mailingliste. Vielen Dank!)
---
Neurosurg Focus. 2003 Feb 15;14(2):e3.
Therapy of glioblastoma multiforme improved by the antimutagenic
chloroquine.Briceño E, Reyes S, Sotelo J.
Neuroimmunology Unit, National Institute of Neurology and
Neurosurgery of Mexico, Mexico City, Mexico.
OBJECT: Therapy of malignant tumors is frequently curtailed by the
emergence of chemoresistant cell clones. Experimentally, the authors
have demonstrated that chemotherapy for glioma in rats is markedly
improved by the administration of the antimutagenic quinacrine. They
studied the effects of chloroquine, an antimutagenic with an optimal
pharmacological profile for human use, as adjuvant for the treatment of
patients with glioblastoma multiforme (GBM).
METHODS: In a prospective controlled randomized trial, 18 patients with GBM
underwent standard treatment with surgery, chemotherapy, and radiotherapy; nine
received an additional 150-mg dose of chloroquine daily starting 1 day
after surgery and continued through the observation period. Nine
matched patients were included as controls. Neuroimaging studies and
clinical response were periodically compared. The follow-up period
ranged from 24 to 50 months. Survival time was defined as the main
outcome measure. Survival was significantly longer in chloroquine-
treated patients than in controls (33 +/- 5 and 11 +/- 2 months,
respectively [p < 0.0002]). At the end of the observation period, four
patients (46%) treated with chloroquine were alive, two had evidence of
tumor remission after 2 years; in another two, tumor recurrence
developed after 2 and 4 years of remission, respectively. No control
patient survived more than 22 months after surgery.
CONCLUSIONS:
Chronic administration of chloroquine greatly enhanced the response of
GBM to antineoplastic treatment. Because the cytotoxicity of chloroquine
on malignant cells is negligible, these favorable results appear mediated
by its strong antimutagenic effect that precludes the appearance of
resistant clones during radiotherapy and chemotherapy.
Surg Neurol. 2007 Apr;67(4):388-91.
Institutional experience with chloroquine as an adjuvant to the therapy
for glioblastoma multiforme.Briceño E, Calderon A, Sotelo J.
Departments of Neuroimmunology and Neurooncology, National
Institute of Neurology and Neurosurgery of Mexico, Mexico City 14269,
Mexico.
BACKGROUND: Results of the current therapy for GBM are dismal; the
mean survival time of patients is approximately 1 year-and it has been
so for several decades. In preliminary studies, we have observed a
potentiating therapeutic effect when chloroquine was added to the
conventional treatment of GBM.
METHODS: Over the last 5 years, 41 patients with GBM received
chloroquine as an optional adjuvant administered concurrently with
conventional surgery, chemotherapy, and radiotherapy. These patients
did not participate in our previous studies on chloroquine administration
and were studied retrospectively;
82 contemporary patients with GBM who did not receive chloroquine
were included in this analysis as control subjects. The end point
observed was time of survival after surgery. RESULTS: Survival time in
patients treated with chloroquine was 25 +/- 3.4 months, as compared
with that of 11.4 +/- 1.3 months in control subjects (P = .000; OR = 0.4;
95% CI = 0.26-0.6); the difference remained significant after regression
analysis for possible clinical confounders.
CONCLUSIONS: In agreement with our recent reports, chloroquine
exerts a strong adjuvant effect when added to the conventional
treatment of GBM. In this large cohort of unselected patients with GBM
who were treated with chloroquine,
the median survival time doubled as compared with that of control
subjects.
Induction of cell death by the anti-malaria agent chloroquine in glioma cells Alf Giese - Department of Neurosurgery, University of Schleswig-Holstein, Campus Lübeck, Lübeck
E. Kim - Department of Neurosurgery, University of Schleswig-Holstein, Campus Lübeck, Lübeck
M. Brockmann - Department of Neuroradiology, University of Schleswig-Holstein, Campus Lübeck, Lübeck
E. Pawlak - Department of Neurosurgery, University of Schleswig-Holstein, Campus Lübeck, Lübeck
M. Ladehoff - Department of Neurosurgery, University of Schleswig-Holstein, Campus Lübeck, Lübeck
Deutsche Gesellschaft für Neurochirurgie. 55. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), 1. Joint Meeting mit der Ungarischen Gesellschaft für Neurochirurgie. Köln, 25.-28.04.2004. Düsseldorf, Köln: German Medical Science; 2004. Doc MO.12.03
The electronic version of this article is the complete one and can be found online at:
http://www.egms.de/en/meetings/dgnc2004/04dgnc0118.shtmlPublished: 23-04-2004
© 2004 Giese et al; licensee german medical science. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
